Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4298445 · 1 trial · 3 indications
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY4298445 (Part A1) | EXPERIMENTAL | Single-ascending dose (SAD) of LY4298445 administered subcutaneously (SC) or intravenously (IV) in healthy participants |
| LY4298445 Placebo (Part A1) | PLACEBO_COMPARATOR | SAD of LY4298445 administered SC or IV in healthy participants |
| LY4298445 (Part A2) | EXPERIMENTAL | SAD of LY4298445 administered SC in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) |
| LY4298445 (Part B) | EXPERIMENTAL | Multiple-ascending doses (MAD) of LY4298445 administered SC in participants with SLE or RA |
| LY4298445 (Part C) | EXPERIMENTAL | Single dose of LY4298445 administered SC in healthy Japanese and, optionally, Chinese participants |
| LY4298445 Placebo (Part C) | PLACEBO_COMPARATOR | Single dose of LY4298445 administered SC in healthy Japanese and, optionally, Chinese participants |
| Name | Type | Description |
|---|---|---|
| LY4298445 | DRUG | Administered SC |
Inclusion Criteria: Healthy Participants Healthy participants between the ages of 18 and 55 years. * Have body weight of at least 50 kilograms (kg) and body mass index (BMI) between 18 and 32 kilogram per square meter (kg/m²), inclusive. Participants with Systemic Lupus Erythematosus (SLE) * Are...
LY4298445 is an investigational small molecule being studied for use in healthy participants and in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). It is being developed by Eli Lilly and Company and is currently in Phase 1 clinical development.
LY4298445 is a small molecule in the immunology therapeutic area. Its specific molecular target has not been disclosed in the available information, so its mechanism of action is not described here.
LY4298445 is being developed by Eli Lilly and Company, a biopharmaceutical company traded on the stock exchange under the ticker LLY. The drug is currently in Phase 1 clinical trials.
LY4298445 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study is currently recruiting participants to evaluate the drug.
LY4298445 is being studied in a Phase 1 clinical trial with the identifier NCT07276958. This trial is recruiting participants and is designed to evaluate the drug in healthy participants and in those with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). The study is being conducted in Australia and China.
LY4298445 is the only name provided for this investigational drug. No alternative names have been mentioned in the available information, so it is not known to be the same as any other drug.